dengue

[Science] Scientists present three crystal structures of full-length dengue virus NS1 complexed with a flavivirus–cross-reactive, NS1-specific monoclonal antibody, 2B7, at resolutions between 2.89 and 3.96 angstroms. These structures reveal a protective mechanism by which two domains of NS1 are antagonized simultaneously.

[iScience] Researchers studied the whole-blood transcriptomic host response to SARS-CoV-2 using RNAseq from 24 healthy controls and 62 prospectively enrolled patients with COVID-19.

[Frontiers in Immunology] Researchers developed mRNA-based JAK-STAT signaling pathway activity assays to quantitatively measure the cellular immune response on Affymetrix expression microarray data of various types of blood samples from virally infected patients, or vaccinated individuals, and to determine vaccine immunogenicity.

[Emergex Vaccines Holding Limited (Globe Newswire, Inc.)] Emergex Vaccines Holding Limited announced that it has raised $11 million in a funding round supported by new and existing investors.The proceeds of this funding round will enable Emergex to further advance and execute its vaccine development strategy, producing vaccine candidates for some of the world’s most threatening and virulent diseases such as COVID-19, Dengue Fever and pandemic flu.

[Scientific Reports] Investigators studied Dengue virus infection of MEG-01 cells to understand its effect on megakaryopoiesis and the generation of platelet-like-particles.

[Heliyon] Investigators assessed the efficiency of dengue virus infection using the novel immortalized human myeloid cell lines iPS-ML and iPS-dendritic cell.